PMID- 36907612
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230316
IS  - 1558-1977 (Electronic)
IS  - 0889-8588 (Linking)
VI  - 37
IP  - 2
DP  - 2023 Apr
TI  - Hematopoietic Stem Cell Transplantation in Thalassemia.
PG  - 413-432
LID - S0889-8588(22)00150-2 [pii]
LID - 10.1016/j.hoc.2022.12.009 [doi]
AB  - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only 
      consolidated, potentially curative treatment for patients with 
      transfusion-dependent thalassemia major. In the past few decades, several new 
      approaches have reduced the toxicity of conditioning regimens and decreased the 
      incidence of graft-versus-host disease, improving patients' outcomes and quality 
      of life. In addition, the progressive availability of alternative stem cell 
      sources from unrelated or haploidentical donors or umbilical cord blood has made 
      HSCT a feasible option for an increasing number of subjects lacking an human 
      leukocyte antigen (HLA)-identical sibling. This review provides an overview of 
      allogeneic hematopoietic stem cell transplantation in thalassemia, reassesses 
      current clinical results, and discusses future perspectives.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Algeri, Mattia
AU  - Algeri M
AD  - Department of Hematology/Oncology, Cell and Gene Therapy - IRCCS, Bambino Gesu 
      Children's Hospital, Rome, Italy. Electronic address: mattia.algeri@opbg.net.
FAU - Lodi, Mariachiara
AU  - Lodi M
AD  - Department of Hematology/Oncology, Cell and Gene Therapy - IRCCS, Bambino Gesu 
      Children's Hospital, Rome, Italy.
FAU - Locatelli, Franco
AU  - Locatelli F
AD  - Department of Hematology/Oncology, Cell and Gene Therapy - IRCCS, Bambino Gesu 
      Children's Hospital, Rome, Italy; Department of Life Sciences and Public Health, 
      Catholic University of the Sacred Heart, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hematol Oncol Clin North Am
JT  - Hematology/oncology clinics of North America
JID - 8709473
SB  - IM
MH  - Humans
MH  - Quality of Life
MH  - Transplantation, Homologous/adverse effects
MH  - *Hematopoietic Stem Cell Transplantation/methods
MH  - *Thalassemia/therapy
MH  - *Graft vs Host Disease
MH  - Transplantation Conditioning/methods
MH  - Unrelated Donors
OTO - NOTNLM
OT  - Cord blood transplantation
OT  - Haploidentical transplantation
OT  - Hematopoietic stem cell transplantation
OT  - Hemoglobinopathies
OT  - Sibling donor transplantation
OT  - Thalassemia
OT  - Unrelated donor transplantation
EDAT- 2023/03/13 06:00
MHDA- 2023/03/15 06:00
CRDT- 2023/03/12 21:55
PHST- 2023/03/12 21:55 [entrez]
PHST- 2023/03/13 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
AID - S0889-8588(22)00150-2 [pii]
AID - 10.1016/j.hoc.2022.12.009 [doi]
PST - ppublish
SO  - Hematol Oncol Clin North Am. 2023 Apr;37(2):413-432. doi: 
      10.1016/j.hoc.2022.12.009.